---

Evaluation of potential antidiabetic activity of abelmoschus esculentus and evidence of possible pharmacokinetic interaction with metformin

---

Original Article

Author Details : Debalina Sardar, Raja Chakraverty*, Pranabesh Chakraborty

Volume : 8, Issue : 4, Year : 2021

Article Page : 263-266

https://doi.org/10.18231/j.ijpp.2021.047

Suggest article by email

Get Permission

---

Abstract

The study is aimed at the evaluation of potential activity of and possible interaction with metformin in animal Models of Diabetes Mellitus. Study objectives include study the anti-diabetic effect of for Diabetes Mellitus in animal models and also to study the effect of Abelmoschus esculentus with metformin and explore any interaction. Plant material was collected () followed by extraction of plant materials () Exudate collection of and activity test study was done (acute toxicity study, according to standard OECD guidelines) Experimental animals were divided into groups. Dosing was done for 28 days. Biochemical parameters were studied. Histopathology studies are done. Results showed that in this study administrations of Abelmoschus esculentus extract (2000mg/kg body weight) Metformin with extract (5mg/kg b.w. and 2000mg/kg body weight and Metformin 5mg/kg body weight decreased elevated blood glucose levels significantly from first to fourth week compared to diabetic control rats and showed minimal safety concerns.

Keywords: Abelmoschus esculentus, Metformin, Antagonism, Diabetes mellitus

How to cite : Sardar D, Chakraverty R, Chakraborty P, Evaluation of potential antidiabetic activity of abelmoschus esculentus and evidence of possible pharmacokinetic interaction with metformin. Indian J Pharm Pharmacol 2021;8(4):263-266

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.